IPO: XDx Seeks Funds To Develop Tests For Organ Transplant Rejection
This article was originally published in The Gray Sheet
Executive Summary
Molecular diagnostics firm XDx is planning an initial public stock offering to support the development of blood tests for predicting organ transplant rejection (see chart: "1IPO Details")
You may also be interested in...
XDx Hopes 510(k) For Heart Transplant Rejection Test Will Aid Reimbursement
Molecular diagnostics firm XDx expects 510(k) clearance for its AlloMap HTx heart transplant rejection test, previously available as a laboratory home-brew, will lead to better reimbursement and market adoption
XDx Hopes 510(k) For Heart Transplant Rejection Test Will Aid Reimbursement
Molecular diagnostics firm XDx expects 510(k) clearance for its AlloMap HTx heart transplant rejection test, previously available as a laboratory home-brew, will lead to better reimbursement and market adoption
FDA Takes Second Stab At Multivariate Diagnostic Oversight Guidelines
FDA cautiously moved ahead with its controversial plan to actively regulate certain laboratory-developed tests with the release of a revised 1draft guidance document July 24